

Genomind’s Cutting-Edge Pharmacogenetic Testing To Be Featured On Educational “Innovations” TV Series

KING OF PRUSSIA, Pa., Dec. 10, 2015 — The largest audience to date will soon learn how personalized medicine for brain health is making a difference for patients. “Innovations,” an award-winning television series seen on the Discovery Channel, will feature Genomind (www.genomind.com) in a seven-minute segment that is set to premiere **Monday, Dec. 14 at 7:30 a.m. EST and 7:30 a.m. PST.**

Genomind’s Genecept Assay™ is a comprehensive genetic test designed to help clinicians optimize treatment decisions for their patients with mental illness. It identifies patient-specific genetic markers that indicate which treatments are likely to work as intended, have no effect or cause adverse effects.

Comments from Vincent Sparks, a patient who benefitted from taking the Assay, are included in the segment. “The testing for me showed right away what issues I was having in terms of what my body was metabolizing, so when the drug was prescribed for me, I felt a change, and I felt I was being more stabilized, so it certainly stopped me on the search for what was the best medication,” he says.

Stephen M. Stahl, M.D., Ph.D., Professor of Psychiatry at the University of California San Diego and Chair, Neuroscience Education Institute, also provides his perspective on the Genecept Assay™. “The genes will tell us whether it’s a little bit more likely or a little less likely that a specific treatment will work *in you*, not another person with the same diagnosis as you,” he says.

The Assay is used to guide treatment for a range of psychiatric conditions, including depression, anxiety, obsessive-compulsive disorder, attention deficit hyperactivity disorder, bipolar disorder, posttraumatic stress disorder, autism and schizophrenia, and has been shown in peer-reviewed published studies to improve patient outcomes and reduce overall medical costs. Further details about the research are available at www.genomind.com/clinical-evidence.

Each Assay provides clinicians with an easy-to-read patient report and a complimentary psychopharmacologist consultation.

About Genomind

Genomind is a personalized medicine company bringing innovation to mental health care through genetic testing. Genomind is comprised of pioneering researchers and thought leaders in psychiatry and neurology and specializes in pharmacogenetic laboratory testing for psychiatry. Genomind is committed to partnering with clinicians to improve their patients’ lives. Learn more at www.genomind.com.

About the Genecept Assay™

The Genecept Assay™ is a genetic test designed to help clinicians optimize treatment decisions for their patients with mental illness. It identifies patient-specific genetic markers that indicate which treatments are likely to work as intended, have no effect or cause adverse effects. It is an easily administered cheek swab test that analyzes key genes that have been selected based on hundreds of studies showing that variations in these genes can inform treatment decisions. The Assay is used to guide treatment for a range of psychiatric conditions, including depression, anxiety, OCD, ADHD, bipolar disorder, PTSD, autism and schizophrenia, and has been shown in peer-reviewed published studies to improve patient outcomes and reduce overall medical costs. Each Assay provides clinicians with an easy-to-read patient report and a complimentary psychopharmacologist consultation. Learn more at www.genomind.com.

About Innovations TV

Innovations, hosted by award winning actor Ed Begley, Jr., is an information-based series geared toward educating the public on the latest breakthroughs in all areas of society. Featuring practical solutions and important issues facing consumers and professionals alike, Innovations focuses on cutting-edge advancements in everything from health and wellness to global business, renewable energy, and more. Learn more at www.InnovationsTelevision.com.

###

Media Contacts:

Kristina Habermann
Vice President, Marketing and Corporate Communications
Genomind
267-326-2166
khabermann@genomind.com

Adam Shapiro
ASPR
202-427-3603
Adam.Shapiro@ASPR.bz